Provided by Tiger Trade Technology Pte. Ltd.

Atrium Therapeutics

13.20
-0.2800-2.08%
Post-market: 13.200.00000.00%19:30 EDT
Volume:180.68K
Turnover:2.39M
Market Cap:225.79M
PE:-3.42
High:13.59
Open:13.53
Low:12.96
Close:13.48
52wk High:16.77
52wk Low:11.13
Shares:17.11M
Float Shares:15.72M
Volume Ratio:0.84
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8578
EPS(LYR):-3.1905
ROE:-43.98%
ROA:-399.25%
PB:1.05
PE(LYR):-4.14

Loading ...

Syngenis banks $4M pre-float to power AI-driven biotech platform

The West Australian
·
Jul 13

Shanghai's Rural Spring Tourism Season Drives 260 Million Yuan in Consumption, Aiming for Sustainable Popularity

Deep News
·
Jul 08

Wave Life Sciences (WVE) Is Up 7.4% After Advancing RNA-Based Obesity Drug Into Phase 2a Trial

Simply Wall St.
·
Jul 05

Does Wave Life Sciences’ (WVE) RNA Obesity Program Signal a Shift in Its Competitive Positioning?

Simply Wall St.
·
Jun 27

ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform

GlobeNewswire
·
Jun 25

Does Labcorp’s New RNA At‑Home ColoSense Screening Win Shift The Bull Case For LH?

Simply Wall St.
·
Jun 24

Atrium Therapeutics grants 8 new hires stock awards including 66,000 options at $12.66

Reuters
·
Jun 24

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 24

Circio boosts share capital as it advances circular RNA therapy platform

TIPRANKS
·
Jun 22

Genflow’s Chair to Spotlight Longevity and RNA Therapeutics at BIO 2026

TIPRANKS
·
Jun 22

Avidity Biosciences Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
Jun 18

TransCode Highlights Progress of Lead RNA Cancer Therapeutic

TIPRANKS
·
Jun 18

Atrium Therapeutics initiated with an Overweight at Cantor Fitzgerald

TIPRANKS
·
Jun 18

Circio raises NOK 620 million in 2026 to accelerate circular RNA gene therapy platform

TIPRANKS
·
Jun 10

Sirnaomics Sets EGM to Revamp Equity Incentive Schemes

TIPRANKS
·
Jun 09

Thalia Therapeutics Showcases RNA Strategy in European Biotech Feature

TIPRANKS
·
Jun 09

EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study

Benzinga_recent_news
·
Jun 03

Thalia Therapeutics Showcases Differentiated RNA Strategy and Cardiovascular Candidate

TIPRANKS
·
Jun 02

Wave Life Sciences to Present at Upcoming Investor Conferences

GlobeNewswire
·
Jun 01

PegBio’s CR059 Wins EASD 2026 Oral Slot, Boosting Circular RNA Metabolic Pipeline

TIPRANKS
·
Jun 01